期刊
JOURNAL OF THORACIC ONCOLOGY
卷 7, 期 9, 页码 1440-1448出版社
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0b013e318260deaa
关键词
Malignant pleural mesothelioma; Biomarker; Folylpoly-gamma-glutamate synthetase; Thymidylate synthase; Pemetrexed
资金
- International Association for the Study of Lung Cancer Fellowship Award
- Specialized Program of Research Excellence Career Development Award
- Louisiana Chapter of the National Lung Cancer Partnership
- Lilly Germany
- Eli Lilly
Background: Pemetrexed-based chemotherapy represents the standard of care in first-line treatment of advanced malignant pleural mesothelioma (MPM). However, there are no established predictors of clinical benefit. Pemetrexed inhibits multiple enzymes involved in pyrimidine and purine synthesis, but the main target is thymidylate synthase (TS). After cellular uptake pemetrexed is converted into more effective polyglutamated forms by folylpoly-gamma-glutamate synthetase (FPGS). We hypothesized that FPGS and TS protein expressions are associated with clinical outcome after pemetrexed-based chemotherapy. Methods: Pretreatment tumor samples from 84 patients with histologically confirmed MPM, who received pemetrexed combined with platinum (79 of 84) or single-agent pemetrexed (5 of 84) as first-line treatment, were retrospectively analyzed. FPGS and TS protein expressions were semiquantitatively assessed by using the Hybrid (H)-scoring system (range, 0-300). H-scores were correlated with radiological response according to modified Response Evaluation Criteria in Solid Tumors, progression-free survival (PFS) and overall survival (OS). Results: Median H-score of the entire cohort was 230 for FPGS (range, 100-300), and 210 for TS (range, 100-300). High FPGS protein expression was significantly associated with longer PFS (p(COX) = 0.0337), better objective tumor response (partial response versus stable disease + progressive disease; p(KW) = 0.003), and improved disease-control rate (partial response + stable disease versus progressive disease; p(KW) = 0.0208), but not with OS. In addition, high TS protein expression was associated with progressive disease under pemetrexed-based therapy (p = 0.0383), and shorter OS (p(COX) = 0.0071), but no association with PFS was observed. Conclusion: FPGS and TS expressions were associated with clinical response and outcome to pemetrexed-based first-line chemotherapy in MPM. Prospective evaluation of FPGS and TS expressions and their prognostic/predictive power in MPM patients is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据